Distribution Agreements in Biopharma

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in distribution dealmaking

• 2.1. Introduction
• 2.2. Definiton of distribution dealmaking
• 2.3. Trends in distribution deals since 2000
• 2.4. Pure deals and multi-component deals
  • 2.5.1. Attributes of pure distribution deals
  • 2.5.2. Attributes of distribution in multi-component deals
• 2.6. Aligning partners to make the distribution agreement work
• 2.7. The emergence of direct to pharmacy distribution in Europe
  • 2.7.1. The role of consolidated distribution

Chapter 3 - Overview of distribution deal structure

• 3.1. Introduction
• 3.2. Pure versus multi-component distribution deals
• 3.3. Pure distribution agreement structure
  • 3.3.1. Example distribution agreements
    • 3.3.1.a. Case study 1: BioSite - Fisher Scientific - January 2006
    • 3.3.1.b. Case study 2: Inverness Medical Innovations - Matritech - November 2006
• 3.4. Distribution rights as part of a wider alliance agreement
  • 3.4.1. Example distribution clauses
    • 3.4.1.a. Case study 3: Ipsen - Aesthetica - March 2006
    • 3.4.1.b. Case study 4: Gilead - Bristol-Myers Squibb - September 2006

Chapter 4 - Leading distribution deals

• 4.1. Introduction
• 4.2. Top distribution deals by value
• 4.3. Top pure distribution deals
• 4.4. Top distribution deals signed by bigpharma
• 4.5. Most active distribution dealmakers
• 4.6. Bigpharma distribution deal activity

Chapter 5 - Bigpharma distribution agreements

• 5.1. Introduction
• 5.2. How to use distribution agreements
• 5.3. Company distribution agreement listings
  • Abbott
  • Actavis
  • Akzo Nobel (Organon)
  • Allergan
  • Altana
  • Amgen
  • Astellas
  • AstraZeneca
  • Baxter International
  • Bayer
  • Bayer Schering Pharma AG
  • Biogen Idec
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Cephalon
  • Chugai
  • CSL
  • Dainippon Sumitomo
  • Eisai
  • Eli Lilly
  • Forest Laboratories
  • Genentech
  • Genzyme
  • Gilead Sciences
  • GlaxoSmithKline
  • Johnson & Johnson
  • King
  • Lundbeck
  • Menarini
  • Merck & Co
  • Merck - Serono KGaA
  • Mitsubishi
  • Novartis AG
  • Novo Nordisk
  • Nycomed Pharma
  • Otsuka
  • Pfizer
  • Procter & Gamble
  • Roche
  • Sanofi-Aventis
  • Schering Plough
  • Serono
  • Shionogi Seiyaku
  • Shire
  • Solvay
  • Takeda
  • Tanabe Seiyaku
  • TAP Pharmaceuticals
  • Teva
  • UCB
  • Watson
  • Wyeth

Chapter 6 - Distribution agreement directory 2003-7

• 6.1. Introduction
• 6.2. Company A-Z
• 6.3. By therapy area
  • Accident/Hospital/Trauma
  • Blood/Lymphatic System
  • Cardiovascular
  • Central nervous System
  • Dermatology
  • Gastrointestinal
  • Genitourinary
  • Genetic
  • Autoimmune/Inflammatory
  • Infection
  • Metabolism
  • Musculoskeletal
  • Oncology
  • Respiratory
  • Sensory Organ / Oral Health
• 6.4. By stage of development at signing
  • Discovery
  • Preclinical
  • Phase I
  • Phase II
  • Phase III
  • Registration
  • Market
• Appendices
  • Appendix 1 - Distribution references
  • Appendix 2 - Resources
  • Appendix 3 - Deal type definitions
  • Appendix 4 - Example distribution contract document
• About CurrentPartnering
• Recent report titles from CurrentPartnering
• Order Form - Reports
• Order form - Company Dealmaking Profiles
• Order Form - Report Update Subscription
• Order Form - CD-Rom

Figures in report

• Figure 1: Definition of distribution dealmaking
• Figure 2: Trends in distribution deal announcements, 2000-2007
• Figure 3: Distribution deals signed at what phase of development, 2000-2007
• Figure 4: Pure versus multi-component distribution deal announcements, 2000-2007
• Figure 5: Stage of development at which pure and multi-component distribution deals are announced 2000-2007
• Figure 6: Issues in implementing distribution agreements
• Figure 7: Recent consolidated distribution deals
• Figure 8: Components of the distribution deal structure
• Figure 9: Top 50 distribution deals by value since 2003
• Figure 10: Top pure distribution deals by value since 2003
• Figure 11: Top distribution deals signed by bigpharma value since 2003
• Figure 12: Most active distribution dealmakers 2003-7
• Figure 13: Characteristics of active distribution dealmakers
• Figure 14: Bigpharma - top 50 - distribution deals since 2003
• Figure 15: Online partnering resources
• Figure 16: Deal type definitions
• Figure 17: Distribution agreement between Amphastar and Andrx, May 2005